SecurityGNMX / Aevi Genomic Medicine, Inc. (58436Q203)
IndustryBiological Products, Except Diagnostic Substances (Biotech)
Common Stock Shares Outstanding59,340,731 shares (as of 2018-06-30)
Total Insiders14
Total Directors9
Total Officers4

Stock Insider Trading (from SEC Form 4)

GNMX / Aevi Genomic Medicine, Inc. Insider Trades

Aevi Genomic Medicine, Inc. insider trades are listed in the following table, followed by a table containing the full transaction history. Insiders are officers, directors, or significant investors in a company. In general, it is generally illegal for insiders to make trades in their companies based on specific, non-public information. This does not mean it is illegal for them to make any trades in their own companies. However, they must report all trades to the SEC via a Form 4.

GNMX / Aevi Genomic Medicine, Inc. insiders include NEIL GARRY ARTHUR, BLECH ISAAC, Piper Brian, COLA MICHAEL F, Children's Hospital of Philadelphia Foundation, CLEMOW ALASTAIR J, Bayley Matthew D, and Applebaum Scott, GANTZ WILBUR H, BARER SOL J, HARPER PHILIP R Duncan Barbara Gayle, BAUER EUGENE A, GRANO JOSEPH J JR, .

Insider Roster

Insider Dir Off 10% Shares Owned
BARER SOL J Director
X 4,098,752
Children's Hospital of Philadelphia Foundation 10% Owner
X 18,424,036
Bayley Matthew D Director
COLA MICHAEL F President and CEO, Director
NEIL GARRY ARTHUR Chief Scientific Officer
Piper Brian CFO & Corporate Secretary
Duncan Barbara Gayle Director
X 71,073
X 5,179,819
Applebaum Scott Chief Legal Officer

Transaction History

Click the link icon to see the full transaction history. Transactions reported as part of a 10b-5 automatic trading plan will have an X in the column marked 10b-5.

Form Insider Code 10b-5 Direct Share
Post Value
2018-08-15 4 Children's Hospital of Philadelphia Foundation P D 0.96 2,551,020 18,424,036 17,687,075
2018-08-15 4 BARER SOL J By: Barer & Son Capital LLC P I 0.96 2,551,020 4,098,752 3,934,802
2017-10-17 4 BARER SOL J P D 1.26 421,032 1,547,732 1,950,142
2017-10-17 4 GRANO JOSEPH J JR P D 1.26 -39,683 113,847 143,447
2017-10-17 4 NEIL GARRY ARTHUR P D 1.26 75,000 114,774 144,615
2017-10-17 4 GANTZ WILBUR H P D 1.26 39,683 71,073 89,552
2017-10-17 4 Duncan Barbara Gayle P D 1.26 59,524 59,524 75,000
2017-10-17 4 CLEMOW ALASTAIR J P D 1.26 19,841 57,536 72,495
2017-10-17 4 BAUER EUGENE A P D 1.26 19,841 165,715 208,801
2017-10-17 4 COLA MICHAEL F P D 1.26 119,047 218,483 275,289
2017-09-01 4 HARPER PHILIP R P D 1.2 83,775 5,179,819 6,215,783
2017-08-23 4 HARPER PHILIP R P D 1.2 5,700 5,096,044 6,115,253
2017-08-22 4 HARPER PHILIP R P D 1.2 4,661 5,090,344 6,108,413
2017-08-10 4 HARPER PHILIP R P D 1.19 20,470 5,085,683 6,051,963
2017-04-28 4 BARER SOL J P D 1.5667 100,000 1,126,700 1,765,201
2017-04-26 4 BARER SOL J P D 1.5434 100,000 1,026,700 1,584,609
2017-03-24 4 HARPER PHILIP R P D 1.6 53,826 5,065,213 8,104,341
2017-03-23 4 HARPER PHILIP R P D 1.6 4,705 5,011,387 8,018,219
2017-03-22 4 HARPER PHILIP R P D 1.79 1,000,000 5,006,682 8,961,961
2016-12-08 4 GRANO JOSEPH J JR P D 5.266 -3,000 74,164 390,548
2015-10-06 4 COLA MICHAEL F P D 6.50 38,460 99,436 646,334
2015-10-06 4 NEIL GARRY ARTHUR P D 6.50 15,384 39,774 258,531
2015-10-06 4 GRANO JOSEPH J JR By family foundation P I 6.50 15,384 71,164 462,566
2015-10-06 4 BARER SOL J By wife P I 6.50 153,846 926,700 6,023,550
2015-09-21 4 BLECH ISAAC By Trust S I 9.96 -94,825 1,802,003 17,947,950
2015-09-21 4 BLECH ISAAC By Trust X I 4.10 230,357 1,896,828
2015-03-20 4 BAUER EUGENE A S D 8.45 -50,000 145,874 1,232,635
2015-03-20 4 BARER SOL J P D 8.45 50,000 772,854 6,530,616
Open market or private purchase of non-derivative or derivative security
Open market or private sale of non-derivative or derivative security
Grant, award, or other acquisition of securities from the company (such as an option)
Conversion of derivative
Sale or transfer of securities back to the company
Payment of exercise price or tax liability using portion of securities received from the company
Gift of securities by or to the insider
Equity swaps and similar hedging transactions
Exercise or conversion of derivative security received from the company (such as an option)
A transaction voluntarily reported on Form 4
Other (accompanied by a footnote describing the transaction)
GNMX: Aevi Genomic Medicine Analysis and Research Report

2018-05-14 - Asif

Overview Aevi Genomic is a clinical stage biopharmaceutical company with an emphasis on identifying the genetic drivers of disease and applying this understanding to the pursuit of differentiated novel therapies primarily for pediatric onset, life-altering diseases, including rare and orphan diseases. The company look to find treatments for genetically defined diseases for which there are limited therapeutic options currently available, with a primary focus on pediatric patients. This strategy begins with identifying and genetically validating a therapeutic target and using genomics to guide product development. The strategy also involves identifying and acquiring otherwise abandoned or overlooked drug candidates and matching targets and mechanisms of action to novel genetic discoveries. Aevi Genomic has partnered with the Center for Applied Genomics, or CAG, at The Children’s Hospital of Philadelphia, or CHOP, to implement a genomic medicine driven approach to drug developm...

Related Articles

BLDP: Ballard Power Systems Analysis and Research Report

2018-08-13 - Asif

Core Business At Ballard, Ballard Power Systems is building a clean energy growth company. Ballard Power Systems is recognized as a world leader in proton exchange membrane (“PEM”) fuel cell power system development and commercialization. The company's principal business is the design, development, manufacture, sale and service of PEM fuel cell products for a variety of applications, focusing on its power product markets of Heavy-Duty Motive (consisting of bus, truck, rail and marine applications), Portable Power, Material Handling and Backup Power, as well as the delivery of Technology Solutions, including engineering services, technology transfer, and the license and sale of its extensive intellectual property portfolio and fundamental knowledge for a variety of fuel cell applications. A fuel cell is an environmentally clean electrochemical device that combines hydrogen fuel with oxygen (from the air) to produce electricity. The hydrogen fuel can be obtained from natural g...

MARA: Marathon Patent Group Analysis and Research Report

2018-08-13 - Asif

Overview Marathon Patent Group was incorporated in the State of Nevada on February 23, 2010 under the name Verve Ventures, Inc. On December 7, 2011, the company changed its name to American Strategic Minerals Corporation and were engaged in exploration and potential development of uranium and vanadium minerals business. In June 2012, the company discontinued its minerals business and began to invest in real estate properties in Southern California. In October 2012, the company discontinued its real estate business when its former CEO joined the firm and the company commenced its IP licensing operations, at which time the Company’s name was changed to Marathon Patent Group, Inc. On November 1, 2017, the company entered into a merger agreement with Global Bit Ventures, Inc. (“GBV”), which is focused on mining digital assets. Marathon Patent Group has since purchased its cryptocurrency mining machines and established a data center in Canada to mine digital assets. Following the me...

ECYT: Endocyte Analysis and Research Report

2018-08-13 - Asif

Business and Organization Endocyte, Inc. is a biopharmaceutical company and leader in developing targeted therapies for the treatment of cancer. The Company uses drug conjugation technology to create novel therapeutics and companion imaging agents for personalized targeted therapies. The agents actively target receptors that are over-expressed on diseased cells relative to healthy cells, such as prostate specific membrane antigen (“PSMA”) in prostate cancer. This targeted approach is designed to safely enable the delivery of highly potent drug payloads. The companion imaging agents are designed to identify patients whose disease over-expresses the target of the therapy and who are therefore more likely to benefit from treatment. In September 2017, the Company entered into a Development and License Agreement (the “License Agreement”) with ABX advanced biochemical compounds – Biomedizinische Forschungsreagenzien GmbH (“ABX”), pursuant to which the Company acquired exclusive ...

Related News Stories

Evaluating KemPharm's KP415, Part 2: The History Of ADHD Treatment And The Competitive Landscape

2018-06-21 seekingalpha
KemPharm will soon publish the results of its Phase 3 clinical trial for KP415, a prodrug of dexmethylphenidate. (73-2)

Aevi Genomic Medicine: Try Subgroups Until It Works?

2018-05-20 seekingalpha
Aevi's current strategy has a reasonable chance of success, but the stock has several red flags and remains highly speculative. (20-0)

Aevi Genomic (GNMX) Presents At Needham And Company 17th Annual Healthcare Conference - Slideshow

2018-03-29 seekingalpha
The following slide deck was published by Aevi Genomic Medicine, Inc. in conjunction with this event. (16-1)

Aevi Genomic Medicine, Inc. 2017 Q4 - Results - Earnings Call Slides

2018-03-14 seekingalpha
The following slide deck was published by Aevi Genomic Medicine, Inc. in conjunction with their 2017 Q4 earnings call. (16-0)

Aevi Genomic Medicine's (GNMX) CEO Mike Cola on Q4 2017 Results - Earnings Call Transcript

2018-03-13 seekingalpha
Aevi Genomic Medicine, Inc. (NASDAQ:GNMX) Q4 2017 Earnings Conference Call March 13, 2018 8:30 AM ET (16-0)